Biosimilars in oncology: much ado about nothing?

Biosimilars have been the subject of an impressive amount of debate since their first introduction in oncology with the development of epoetins in 2007 and later granulocyte-colony stimulating factors. In this journal there have been authoritative reviews 10 years ago [1] and opinions [2] expressing doubts about the development process and the manner in which these agents are introduced into clinical practice. Fortunately, as of today, the manner in which the European Medicines Agency approves such agents [3] has not been found to be at fault.